Member Info for lordloadsoflolly

JH - thanks.

Sounding good!

Can anyone with experience explain this part of the RNS:

“With the well already open for nearly three weeks and high quality helium shows in the primary target horizon, and oil shows within the Nisku and Duperow formations, the Company decided to not drill test the Flathead formation in this well. Upside potential in the Flathead remains open and will be tested in a future production well.”

What reasons would they have had not to drill test the Flathead at Linda#1 now, given its upside potential?

TheWigster - agreed; £3m highly unlikely this year.

But if Morepen's forecast in your link is right, Opti might smash that in a few years' time: "Morepen forecasting £17m+ in 3-5 years". Depending on Opti's slice of the Morepen cake of course.

Mind, we HAVE heard similar impressive forecasts before.........

3LB - I agree enthusiasm’s fine. But over-exuberant animal spirits are not.

On a couple of occasions DM has lapsed into the latter, giving out what later transpired to be false hope.

That damages investor confidence and has probably contributed to HEX’s muted SP ever since, despite the very significant progress made.

Cm22 - TEK now only holds around 10% of Innovative Eyewear anyway.

So its SP won’t be hugely affected by anything I.E. does.

Morri940 - my gut feeling is your gut feeling has a 50% chance of being right.

H&T released details of its 2025 Performance Share Plan (PSP) today for Executive Directors & Senior Management.

This grants them free shares (options) in April 2028, subject to various criteria being met - including continued H&T employment.

There are three different thresholds for qualification (Minimum, Target & Maximum). These thresholds reference both Total Shareholder Return (TSR) and EPS growth. The greater the growth, the more options they receive.

The scheme is split equally (50/50) based on targets for total shareholder return (TSR) and growth in basic earnings per share (EPS) between 1st January 2025 & 30th September 2027.

2024:

47% Minimum TSR growth needed to qualify for ANY options (30% of max. award)

28% Minimum EPS growth needed to qualify for ANY options (30% of max. award)

2025:

30% Minimum TSR growth needed to qualify for ANY options (30% of max. award)

30% Minimum EPS growth needed to qualify for ANY options (30% of max. award)

2025's Minimum TSR growth qualifier is LESS demanding than 2024's

2025's Minimum EPS growth qualifier is MORE demanding than 2024's

2024:

53% Target TSR growth needed to qualify for 50% of maximum award

36% Target EPS growth needed to qualify for 50% of maximum award

2025:

50% Target TSR growth needed to qualify for 50% of maximum award

50% Target EPS growth needed to qualify for 50% of maximum award

2025's Target TSR growth qualifier is LESS demanding than 2024's

2025's Target EPS growth qualifier is MORE demanding than 2024's

2024:

63% Maximum TSR growth needed to qualify for 100% of maximum award

45% Maximum EPS growth needed to qualify for 100% of maximum award

2025:

100% Maximum TSR growth needed to qualify for 100% of maximum award

100% Maximum EPS growth needed to qualify for 100% of maximum award

2025's Maximum TSR growth target is MORE demanding than 2024's

2025's Maximum EPS growth target is MORE demanding than 2024's

CONCLUSIONS:

For H&T employees to benefit most from the new scheme, EPS over the period needs to rise MORE than 2024's Performance Share Plan.

2025 Total Shareholder Return qualifying thresholds are much more lenient at the Minimum level & slightly more lenient at Target level. But much more demanding at Maximum level.

I like the fact there's a further two year share retention period for any options awarded under the scheme. And that it targets both company performance & staff continuity.

For the most part, it also sets a higher bar for qualification under the new scheme compared to 2024, which is encouraging.

Mol42 - thanks for that summary.

Q1 25 orders had supposedly passed H1 24 (£276k) by 18th March 25.

I can see FY 25 turnover exceeding previous years. Around £1.5m would be my guess. But £3m? Highly unlikely methinks.

Ezhik - hopefully No More Tears at any rate.

TW - yes things are moving in the right direction. But there’s an awfully long way to go still.

Take a good look at their income statements over the past 4 years:

www.hl.co.uk/shares/shares-search-results/o/optibiotix-health-plc-ord-2p/financial-statements-and-reports

Expenses outweigh revenues in every year bar one. And that only because of a revaluation of one of their holdings. So your argument about SBTX sales having been used purely to fund orders doesn’t stack up.

I’d say the current SP is about right unless/until we either get significantly higher revenues or a Sweetbiotix deal.

Scrodingerscat - I hope you’re not casting nasturtiums on our world-renowned poster, multibagger & Buffett-beater - aka Tigger.

Many’s the time I’ve picked up invaluable share tips from him & his jungle mates as we strolled along the pier at Weston Super Merde. Nudgy nudgy, rumbly in the jungly.

Morning hulltiger - you’ll be pleased to hear you’re MUCH higher up the animal kingdom than a certain poster we could mention (nudgy nudgy).

Avocet - OK, maybe exponential was the wrong word to use.

Fact remains, 5.7 times not very much still equals not very much. Especially when you’ve a very concentrated (i.e. riskily small) number of customers & a market cap of c. £30m.

Rather than reading the RNS, try Googling Tate & Lyle’s failed attempt at marketing Soda-Lo (a very similar micro crystal low sodium salt). Spoiler alert: it doesn’t have a terribly happy ending.

Hulltiger - no relation to Tigger I take it?

Talking of whom. Where’s Tigger? Here Tiggy Tiggy Tiggy.

Oh wait, I remember now. He told us he was stalking other prey (most of which appear to die no sooner has he pounced).

Still, no doubt he’ll leap back here the moment there’s another temporary upward blip, telling us he bought back in just beforehand. ‘Cos Tigger’s clever like that.

Shareprof1 - how do you arrive at a £20m+ valuation - excl. Opti’s other holdings - when you estimate sales (not profit) of around £2m?

OrangeMoon - January’s £5m placing may well cover any extra Linda compression costs.

Either way, if Linda comes in much higher than anticipated, that would be a nice problem to have!

Avocet - potential's one thing, actual sales quite another.

And when you've a market cap of c. £30m, investors are already assuming exponential* sales growth (*which has yet to materialise, despite the latest RNS).

DropD - it would appear Tina Brave isn’t very - errrrr - brave after all. Or consistent.

Only this morning (s)he posted: “ Wow and wow and erm wow. This is going to blow the doors off any AIM share... Bravo all 👏”

Now (s)he’s telling us Hex will “fail to produce this summer”.

Make yer mind up love. Second thoughts, don’t bother - just give us all a rest.

Bye bye Tina. Filtered.

TinaB - yes, all pretty unsubtle from JH really.

He tends to get a teensy bit peeved when questioned though. Bovvered, am I? Hard hats optional, I say.

There'll always be periods of institutional buying & selling. Especially with a share like this.

Anyone claiming the latest IPO seller's out will only remain right until the next big trade comes along. Just gotta stop obsessing, live with it & focus on the bigger picture (i.e. the overall trajectory).

Now, where did I put that hard hat?

Any post with "Tim said" in it is off to a bad start.